Information  X 
Enter a valid email address

Uniphar PLC (UPR)

  Print   

Wednesday 12 May, 2021

Uniphar PLC

Result of AGM

RNS Number : 4280Y
Uniphar PLC
12 May 2021
 

 

 

AGM Results

 

Dublin, London | 12 May 2021

 

 

Uniphar plc is pleased to announce that at the Annual General Meeting held at 11.00 a.m. today, 12 May 2021, each of the resolutions set out in the Notice of Annual General Meeting circulated to shareholders and made available on the Company's website, www.uniphar.ie , were duly passed without amendment.

 

Details of votes cast are set out below:

 


RESOLUTION

TOTAL

FOR

%

AGAINST

%

ABSTAIN

1

Financial Statements and Reports

137,296,226

135,574,392

98.75

1,721,834

1.25

20,532

2

Final Dividend of €4.2m

137,296,226

137,293,095

100.00

3,131

0.00

20,532

3(a)

Re-elect Tim Dolphin

137,316,758

137,242,840

99.95

73,918

0.05

0

3(b)

Re-elect Padraic Dempsey

137,316,758

137,242,840

99.95

73,918

0.05

0

3(c)

Re-elect Paul Hogan

137,316,758

136,410,522

99.34

906,236

0.66

0

3(d)

Re-elect Maurice Pratt

137,316,758

137,219,247

99.93

97,511

0.07

0

4(a)

Elect Jeff Berkowitz

137,316,758

137,284,424

99.98

32,334

0.02

0

4(b)

Elect Jim Gaul

137,316,758

137,284,424

99.98

32,334

0.02

0

4(c)

Elect Liz Hoctor

137,316,758

137,293,695

99.98

23,063

0.02

0

5

Remuneration of Auditors

125,264,944

119,641,181

95.51

5,623,763

4.49

12,051,814

6

Allot relevant securities

137,296,100

135,196,092

98.47

2,100,008

1.53

20,658

7

Disapplication of pre-emption rights in specified circumstances

137,264,600

137,241,537

99.98

23,063

0.02

52,158

8

Disapplication of pre-emption rights in additional circumstances

137,264,600

137,185,914

99.94

78,686

0.06

52,158

9

Authorise market purchases of the Company's Ordinary Shares

137,304,627

137,281,564

99.98

23,063

0.02

12,131

10

Re-issuance of Treasury Shares

137,304,627

137,281,564

99.98

23,063

0.02

12,131

 

 

--- ENDS ---

 

For further details contact:

 

Uniphar

+353 (0) 1 428 7777



Brian O'Shaughnessy


Group Director of Corporate Development

[email protected]



 

Davy

 

+353 (0) 1 679 6363

(Joint Broker, Nominated Adviser and Euronext

Growth Adviser)




Fergal Meegan


Barry Murphy


Niall Gilchrist




RBC Capital Markets (Joint Broker)

+44 (0) 20 7653 4000



Jonathan Hardy


Jamil Miah

Priyal Soni

 


Stifel Nicolaus Europe Limited (Joint Broker)

+44 (0) 20 7710 7600

Matt Blawat


Ben Maddison


Francis North




Q4 PR

+353 (0) 1 475 1444 or

(Public Relations Adviser to Uniphar)

+353 87 235 6461



Iarla Mongey


 

About Uniphar plc

 

Headquartered in Dublin, Ireland, Uniphar is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,600, the Group is active in Ireland, the UK, the Benelux, the Nordics and the US.

 

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability.

 

Commercial & Clinical  

In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in Ireland, the UK, Benelux, the Nordics and the US, the Group is growing with its clients to provide pan-European solutions. Uniphar has built a fully integrated multi-channel solution that is supported by our highly experienced and clinically trained teams leveraging our digital technology and insights which allows us to deliver consistently exceptional outcomes for our clients.  

 

Product Access  

n Product Access the Group is growing two distinct service offerings: 1) "On Demand Access", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.

 

Supply Chain & Retail  

Uniphar is an established market leader in Ireland with over a 50% market share in the wholesale/hospital market, supported by a network of c.330 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the manufacturer relationships and infrastructure are utilised for the benefit of the growth divisions, Commercial & Clinical and Product Access.  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGFLFLSEIIFLIL

a d v e r t i s e m e n t